Hopefully the Ozempic breakthroughs will alleviate some of the need for kidney donation as it lowers the occurrences of End-Stage Renal Disease (ESRD).
> Based on the trial’s design, Ozempic needed to reduce the absolute risk of one of those kidney-related conditions by at least 3.5% when compared to placebo, or a relative risk reduction of around 16.5%, Akash Tewari, a Jefferies analyst who covers Lilly, wrote in a note to clients.
https://www.biopharmadive.com/news/novo-nordisk-ozempic-kidn...